Creating a biomarker to understand how opioid antagonists work in adolescents with eating disorders
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents with Eating Disorders
This study is looking to find a way to better understand how certain medications can help teenagers with eating disorders like Anorexia Nervosa and Binge Eating Disorder, so we can improve their treatment options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Children's Mercy Hosp (Kansas City, Mo) NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-11094935 on NIH RePORTER |
What this research studies
This research focuses on developing a pharmacodynamic biomarker that can help measure the effects of opioid antagonists in treating adolescents with eating disorders such as Anorexia Nervosa and Binge Eating Disorder. The study aims to enhance early-stage drug development by using advanced techniques in neuroimaging and clinical trials specifically tailored for young patients. By understanding how these medications interact with the brain, the research seeks to improve treatment options for adolescents struggling with these serious conditions. The project is led by Dr. Stephani Stancil, who is dedicated to advancing pediatric neuropsychopharmacology.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents aged 12 to 20 who are diagnosed with eating disorders such as Anorexia Nervosa or Binge Eating Disorder.
Not a fit: Patients outside the adolescent age range or those not diagnosed with eating disorders may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for adolescents with eating disorders, potentially reducing their symptoms and improving their quality of life.
How similar studies have performed: While the development of pharmacodynamic biomarkers is a growing field, this specific approach targeting adolescents with eating disorders is relatively novel and has not been extensively tested in prior research.
Where this research is happening
Kansas City, United States
- Children's Mercy Hosp (Kansas City, Mo) — Kansas City, United States (Active)
Researchers
- Principal investigator: Stancil, Stephani L — Children's Mercy Hosp (Kansas City, Mo)
- Study coordinator: Stancil, Stephani L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.